Cognitive testing in a structured and standardized way at a defined group of patients with cognitive dysfunction, with a shared molecular etiology .The intended objectives are:- Detailed human neurocognitive profile defining for each genetic defect…
ID
Source
Brief title
Condition
- Chromosomal abnormalities, gene alterations and gene variants
- Developmental disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
neurocognitive profiles
Secondary outcome
-Identification of neurocognitive markers as endophenotypes in different
neuropsychiatric diseases caused by EHMT1 defects (ID, schizophrenia and
autism).
- Identification of cross species neurocognitive markers in EHMT1 defects
Background summary
Genetic factors contribute significantly to the aetiology of neuropsychiatric
disorders. These factors are multifactorial, which results in any clear
relationship between the genetic defects and the range of neuropsychiatric
outcomes.
In recent years, next generation sequencing has revolutionized the
identification of causative genetic mutations. These result in a wide and
intense range of neuropsychiatric outcomes. In animal research this has been
carefully elaborated. To translate these results into human results, it is
necessary to carry out tests in humans.
By precisely identifying the pathophysiological mechanisms of this specific
genetic defects, we're able to identify neurocognitive profiles. This may offer
clues for future research.
See also the application form in the appendix.
Study objective
Cognitive testing in a structured and standardized way at a defined group of
patients with cognitive dysfunction, with a shared molecular etiology .
The intended objectives are:
- Detailed human neurocognitive profile defining for each genetic defect.
- Identification of translational neurocognitive endophenotypes between species.
- Gain insight in cognitive endophenotypes of neuropsychiatric syndromes with a
shared etiology.
See also the application form in the appendix.
Study design
Population: n = at least 60 subjects.
Measures:
- Cognitive tests:
1. parts of the CANTAB: CAmbridge Neuropsychological Test Automated Battery
(CANTAB (Owen, Downes, Sahakian, Polkey, & Robbins, 1990). This is a computer
tablet based cognitive assessment battery, which investigates attention, memory
and reaction time.
2. parts of the ADOS: Autism Diagnostic Observation Schedule (Lord et al.,
1989) is a structured and standardized psychiatric observation and examination
for assessing characteristics of autism.
- Phenotypic testing:
1.clinical interviews
a. The Vineland Adaptive Behavior Scale (VABS) (Sparrow, 1984) will be used
to determine the adaptive functioning of people with an intellectual
disability.
b. The mini Psychiatric Assessment Schedules for Adults with Developmental
Disabilities (mini PAS-ADD) (Moss S., 1997) to determine behavioral problems
and psychiatric disease in subjects with an intellectual disability by
interviewing the proxy.
2.child psychiatric examination: the participant is asked to sing, draw, play
with a doll and tea set, puzzle together with the investigator to assess the
level of functioning, motor skills, language skills and social emotional
skills.
3.questionnaires, which are completed by proxy of the participants:
a. CBCL: questions about problem behavior.
B.SCQ: questions about autistic features
c.temperament questionnaire
d. Questionnaire about socio-economic features.
e. Development questionnaire
See also the application form in the appendix.
Study burden and risks
There aren't any risks associated with participation.
The toys used for playing are approved for children and don't contain any small
parts, which can be dangerous.
Reinier Postlaan 12
Nijmegen 6525 GC
NL
Reinier Postlaan 12
Nijmegen 6525 GC
NL
Listed location countries
Age
Inclusion criteria
-Presence of one of the following specific genetic variants
- EHMT1 mutation (Kleefstra Syndrome)
- KANSL1 mutation (Koolen-deVries syndrome)
- ABJRD11 mutation (KBG syndrome)
- 15q13 mutation ( Prader-Willi syndrome)
- Trisomie 21 (syndroom van Down).;-biological age above 3 years
Exclusion criteria
Multiple genetic defects within one subject
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL43187.091.13 |